[(1R)-3-oxo-1H-2-benzofuran-1-yl] 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate
| Title | Journal |
|---|---|
| Contribution of pH to systemic exposure of niflumic acid following oral administration of talniflumate. | European journal of clinical pharmacology 20110401 |
| Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors. | Bioorganic & medicinal chemistry letters 20091201 |
| Determination of talniflumate and niflumic acid in human plasma by liquid chromatography-tandem mass spectrometry. | Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20090401 |
| Liquid chromatography-mass spectrometric method for the sensitive determination of niflumic acid in human plasma and its application to pharmacokinetic study of talniflumate tablet. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081215 |
| Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate. | European journal of clinical pharmacology 20081001 |
| Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome. | The Journal of pharmacology and experimental therapeutics 20060401 |
| Quantitation of niflumic acid in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection and its application to a bioequivalence study of talniflumate tablets. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050725 |
| Simultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography. | Biomedical chromatography : BMC 20050101 |
| Talniflumate (Genaera). | Current opinion in investigational drugs (London, England : 2000) 20040501 |